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Atrial fibrillation accounts for a substantial proportion of ischemic strokes of known
etiology and may be responsible for an additional subset of the 25–40% of strokes
of unknown cause (so-called cryptogenic). Oral anticoagulation is significantly more
effective than antiplatelet therapy in the secondary prevention of atrial fibrillation-related
strokes, providing justification for developing more sensitive approaches to detecting
occult paroxysms of atrial fibrillation. In this article, we summarize the current state of
knowledge regarding the value of in-hospital and out-patient monitoring for detecting
atrial fibrillation in the context of cryptogenic stroke. We review the evidence for
and against screening with standard Holter monitors, external loop recorders, the
newer real-time continuous attended cardiac monitoring systems, cardiac implantable
electronic devices, and insertable loop recorders. We review key questions regarding
prolonged cardiac arrhythmia monitoring, including the relationship between duration of
the atrial fibrillation episode and risk of thromboembolism, frequency of monitoring and
its impact on the diagnostic yield in detecting occult or subclinical atrial fibrillation, and
the temporal proximity of device-detected atrial fibrillation to stroke events. We conclude
by proposing avenues for further research.
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Introduction
Cryptogenic stroke (CS) refers to cerebral ischemia of obscure or unknown mechanism. Specif-
ically, it is defined as cerebral infarction that despite extensive evaluation is not attributable to
a definite source of cardioembolism, large artery atherosclerosis, or small vessel disease (lacunar
infarct) (Adams et al., 1993). Based on contemporary estimates, approximately 25–40% of ischemic
strokes are cryptogenic (Sacco et al., 1989; Petty et al., 1999; Kolominsky-Rabas et al., 2001; Lee
et al., 2001; Liao et al., 2007). The underlying mechanism of CS is often not identified because (1)
the inciting mechanism for ischemia may be transitory [e.g., paroxysmal atrial fibrillation (AF)] or
reversible (e.g., drug-induced vasculopathy), (2) investigations performed did not explore all pos-
sible etiologies (e.g., no blood cultures performed in the context of an infectious endocarditis), or
(3) the cause remains truly unknown.
It has been postulated that additional extended electrocardiographic monitoring may identify
etiologic paroxysmal AF in a subset of strokes initially categorized as cryptogenic. While AF is
a common cause of ischemic stroke, representing approximately 50% of cardioembolic strokes
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and 20% of all strokes, underdetection remains problematic given
its unreliable symptom profile (i.e., poor correlation between
symptoms and AF episodes), coupled with its intermittent nature
(paroxysmal AF is, by definition, a disease of episodic clusters)
(Page et al., 1994; Kottkamp et al., 2004; Piorkowski et al., 2005;
Strickberger et al., 2005; Ziegler et al., 2006; Cotter et al., 2013;
Verma et al., 2013).
In the context of AF, oral anticoagulation reduces stroke and
systemic embolic risk by two-thirds (Hart et al., 2007). Con-
versely, antiplatelet therapy, which remains the treatment of
choice for an ischemic stroke not attributable to a major-risk
cardioembolic source, is far less effective for secondary preven-
tion in AF (Connolly et al., 2006). Consequently, if AF remains
undetected, secondary prevention therapy is often suboptimal.
The importance of detecting occult AF is critical considering
that, compared with ischemia due to other mechanisms, AF-
related strokes are associated with a higher recurrence rate over
the short and long term, and greater severity. Specifically, an
AF-related stroke is associated with significantly greater morbid-
ity and long-term disability, increased in-hospital mortality, and
a higher index of fatal recurrence (Bruggenjurgen et al., 2007;
Winter et al., 2009). Thus, identification of appropriate can-
didates for anticoagulation is paramount for prevention of
AF-associated thromboembolism.
In-Hospital and brief Monitoring for
Detection of AF in Patients with
Cryptogenic Stroke
Post-stroke in-hospital rhythm monitoring is limited by a finite
window of observation, which is particularly problematic in the
context of intermittent AF. The detection rate of new paroxys-
mal AF (i.e., AF not previously identified by history or ECG)
from a standard 12-lead ECG after ischemic stroke or transient
ischemic attack (TIA) is estimated at 2–4% (Bell and Kapral,
2000; Jabaudon et al., 2004; Ritter et al., 2013). Conversely, con-
tinuous cardiac rhythm monitoring (CCM) for 28–72 h after
index hospital admission has been reported to detect new AF in
up to 2.4–18.5% of patients with acute ischemic stroke (Table 1)
(Rem et al., 1985; Barthelemy et al., 2003; Sulter et al., 2003;
Bansil and Karim, 2004; Adams et al., 2007; Vivanco Hidalgo
et al., 2009; Rizos et al., 2010, 2012; Gumbinger et al., 2012;
Kallmunzer et al., 2012; Lazzaro et al., 2012; Fujii et al., 2013;
Ritter et al., 2013; Sutamnartpong et al., 2014). Despite such
early intense monitoring, a substantial proportion of patients
at risk for recurrent cardioembolism from occult AF remain
undiagnosed.
In patients with cryptogenic stroke in whom AF is suspected,
an increased intensity of arrhythmia monitoring is generally
recommended. Unfortunately, the optimal timing (e.g., from
the index stroke), the method, and duration of monitoring to
maximize detection of occult AF remain unclear. Traditionally,
24-h ambulatory ECG (Holter) monitoring has been employed,
though the utility of Holter monitoring is limited by low
rates of arrhythmia detection (∼4%, Table 2), inadequate neg-
ative predictive value, and poor cost-effectiveness in unselected
patients (Rem et al., 1985; Kessler and Kessler, 1995; Hornig et al.,
1996; Schuchert et al., 1999; Barthelemy et al., 2003; Jabaudon
et al., 2004; Schaer et al., 2004; Shafqat et al., 2004; Gunalp et al.,
2006; Tagawa et al., 2007; Douen et al., 2008; Stahrenberg et al.,
2010; Dangayach et al., 2011; Doliwa Sobocinski et al., 2012;
Gumbinger et al., 2012; Lazzaro et al., 2012; Rizos et al., 2012;
Ritter et al., 2013; Gladstone et al., 2014; Thakkar and Bagarhatta,
2014). As a result, clinical risk scores to help identify stroke
patients at risk for paroxysmal AF were developed (Table 3)
(Suissa et al., 2009; Fujii et al., 2013). Likewise, Wallmann et al.
(2007) described findings on 24-h Holter monitoring (i.e., >70
premature atrial beats per 24 h) that predicted improved detec-
tion of AF (26%) when monitoring was extended to 7 days.
Offering credence to the concept of pre-selecting patients for
monitoring, a recentmeta-analysis of 32 studies (observational or
randomized studies of patients with ischemic stroke who under-
went any cardiac monitoring for a minimum of 12 h) reported
significantly greater detection rates of occult AF in selected
(13.4%; 95% CI 9.0–18.4%) when compared to unselected (6.2%;
95% CI 4.4–8.3%) subjects (Kishore et al., 2014).
Outpatient Event Monitoring for Detection
of AF in Patients with Cryptogenic Stroke
Given that arrhythmia detection is related to total AF burden and
improves with increasing intensity of monitoring, various strate-
gies of prolonged monitoring have been employed. Event loop
recorders (ELRs) are external devices that allow up to 30 days
of cardiac rhythm recording. Several studies have evaluated their
utility in patients with cryptogenic stroke despite standard diag-
nostic procedures including telemetry and/or Holter monitoring.
Barthelemy et al. (2003) detected paroxysmal AF in 14.3% of 28
patients by ELR monitoring (24–162 h). Jabaudon et al. (2004)
and Wallmann et al. (2007) employed 7-day ambulatory ECG
monitoring in 149 and 127, patients respectively, detecting occult
AF in 5.7 and 14.2%, respectively. In the latter study, AF was
detected in 26% of patients with frequent APBs (>70/24 h) but
only in 6.5% when APBs were infrequent. Two further obser-
vational studies examined the incremental role of prolonged
(30-day) ELR monitoring after standard diagnostic procedures,
documenting a new diagnosis of occult AF in 7–20% of patients
(Elijovich et al., 2009; Flint et al., 2012).
In response to these observational studies, the open-label,
multi-center, randomized controlled “30-Day Cardiac Event
Monitor Belt for Recording Atrial Fibrillation after a Cerebral
Ischemic Event (EMBRACE)” trial enrolled 572 subjects with no
history of AF and cryptogenic stroke or TIA of undetermined
cause within the previous 6 months (Gladstone et al., 2014). Of
note, transesophageal echocardiography or intracranial vascular
imaging was not required as part of the stroke workup. Patients
were randomly assigned to non-invasive ambulatory ECG mon-
itoring with a 30-day event-triggered loop recorder (ELR group)
vs. conventional 24-h Holter monitoring (control). At 30 days,
AF lasting 30 s or longer was detected in 16.1% in the ELR-
group, as compared with 3.2% in the control group (P < 0.001;
number needed to screen of 8). Episodes of AF lasting ≥2.5min
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TABLE 1 | Short-term monitoring and AF detection.
Sources Intervention Duration of monitoring N AF Detected (%)
Bansil and Karim (Bansil and Karim, 2004) CCM NA 121 4.9
Barthelemy (Barthelemy et al., 2003) CCM 70h 52 7.7
Gumbinger (Gumbinger et al., 2012) CCM 24h 312 11.9
Kallmunzer (Kallmunzer et al., 2012) CCM 76h 271 6.6
Lazzaro (Lazzaro et al., 2012) CCM 73h 133 6.0
Rem (Rem et al., 1985) CCM 48h 169 2.4
Rizos (Rizos et al., 2010) CCM 48h 136 21.3
Rizos (Rizos et al., 2012) CCM 64h 496 5.4
Ritter (Ritter et al., 2013) CCM 72h 1110 1.3
Sulter (Sulter et al., 2003) CCM 48h 27 18.5
Sutamnartpong (Sutamnartpong et al.,
2014)
CCM 24h 204 5.8
Vivanco (Vivanco Hidalgo et al., 2009) CCM 55h 465 7.1
Fudji (Fujii et al., 2013) CCM or Holter NA 113 11.5
Barthelemy (Barthelemy et al., 2003) Holter 24 h 55 5.5
Douen (Douen et al., 2008) Holter 24 h 126 9.5
Gladstone (Gladstone et al., 2014) Holter 24 h 277 3.2
Gumbinger (Gumbinger et al., 2012) Holter 24 h 192 1.0
Gunalp (Gunalp et al., 2006) Holter 24 h 26 42.3
Hornig (Hornig et al., 1996) Holter 24 h 261 3.8
Jabaudon (Jabaudon et al., 2004) Holter 24 h 139 5.0
Kessler (Kessler and Kessler, 1995) Holter 24 h 93 0.0
Lazzaro (Lazzaro et al., 2012) Holter 24 h 133 0.0
Rizos (Rizos et al., 2012) Holter 24 h 496 2.8
Ritter (Ritter et al., 2013) Holter 24 h 1110 0.5
Schaer (Schaer et al., 2004) Holter 24 h 425 2.1
Shafqat (Shafqat et al., 2004) Holter 24 h 210 2.4
Sobocinski (Doliwa Sobocinski et al.,
2012)
Holter 24 h 249 2.0
Stahrenberg (Stahrenberg et al., 2010) Holter 24 h 224 4.8
Tagawa (Tagawa et al., 2007) Holter 24 h 299 8.4
Thakkar (Thakkar and Bagarhatta, 2014) Holter 24 h 52 5.8
Rem (Rem et al., 1985) Holter 24–48 h 51 3.9
Dangayach (Dangayach et al., 2011) Holter 48 h 51 23.6
Stahrenberg (Stahrenberg et al., 2010) Holter 48 h 224 6.4
Schuchert (Schuchert et al., 1999) Holter 72 h 82 6.1
Stahrenberg (Stahrenberg et al., 2010) Holter 7 d 224 12.5
Ritter (Ritter et al., 2013) Holter 7 d 60 1.7
MCOT, mobile cardiac outpatient telemetry; ICM, implantable cardiac monitor; ELR, external loop recorder; NA, not available.
were noted in 9.9% in the ELR-group, as compared with 2.5%
in the control group (P < 0.001). By 90 days, oral antico-
agulant therapy had been prescribed for more individuals in
the ELR-group than in the control group (18.6 vs. 11.1%; P =
0.01), presumably because of the higher rates of AF detection.
Building on the observational evidence, the EMBRACE study
demonstrated that the 30-day event-triggered recorder was sig-
nificantly more effective than conventional 24-h Holter monitor-
ing for identification of AF in patients with recent cryptogenic
stroke.
Outpatient Telemetry for Detection of AF in
Patients with Cryptogenic Stroke
Real-time continuous attended cardiac monitoring systems (e.g.,
Mobile Cardiac Outpatient Telemetry or MCOT) represent a
novel form of monitoring that is designed to address the limita-
tions of standard Holter and ELR monitoring. Specifically, while
they record automatic and patient triggered events similar to an
ELR, the information is sent to a central monitoring station for
analysis and transmitted to the treating physician. Several studies
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TABLE 2 | Medium and long-term monitoring and AF detection.
Sources N AF Definition Intervention Duration of monitoring AF detected (%)
Barthelemy (Barthelemy et al., 2003) 28 30 s ELR 70 h 14.3
Jabaudon (Jabaudon et al., 2004) 88 “seconds” ELR 7 d 5.7
Wallman (Wallmann et al., 2007) 127 30 s ELR 7 d 14.2
Elijovich (Elijovich et al., 2009) 20 30 s ELR 30 d 20.0
Flint (Flint et al., 2012) 236 30 s ELR 30 d 7.0
Gaillard (Gaillard et al., 2010) 98 30 s TTM 30 d 9
Gladstone (Gladstone et al., 2014) 280 30 s ELR 30 d 16.1
2.5min 9.9
Bhatt (Bhatt et al., 2011) 62 30 s MCOT 28 d 24
5min 9
Kamel (Kamel et al., 2013) 20 30 s MCOT 21 d 0.0
Miller (Miller et al., 2013) 156 30 s MCOT 30 d 5
Tayal (Tayal et al., 2008) 56 30 s MCOT 21 d 5
Christensen (Christensen et al., 2014) 85 2min ICM 19m 16.1
Cotter (Cotter et al., 2013) 51 2min ICM 7.6m 25.5
Dion (Dion et al., 2010) 24 30 s ICM 14.5m 0.0
Etgen (Etgen et al., 2013) 22 6min ICM 12m 27.3
Ritter (Ritter et al., 2013) 60 2min ICM 12.8m 16.7
Rojo-Martinez (Rojo-Martinez et al., 2013) 101 2min ICM 9.4m 33.7
Sanna (Sanna et al., 2014) 221 2min ICM 6m 8.9
MCOT, mobile cardiac outpatient telemetry; ICM, implantable cardiac monitor; ELR, external loop recorder.
have highlighted the utility of MCOT in detecting occult AF in
the context of cryptogenic stroke with an unrevealing arrhythmia
investigation, with an incidence of approximately 9% (ranging
from 0–24%; Table 2) (Tayal et al., 2008; Bhatt et al., 2011; Kamel
et al., 2013;Miller et al., 2013). In these series, the time to arrhyth-
mia detection was protracted, suggesting improved arrhythmia
detection with prolonged monitoring (>7 days). Unfortunately,
compliance with prolonged MCOT monitoring is suboptimal,
with approximately 80% of patients completing at least 14 days
and 62% at least 21 days in the largest reported series (Miller et al.,
2013).
AF Detection on Cardiac Implantable
Electronic Devices (CIED)
Continuous ECG monitoring via CIEDs (e.g., pacemakers or
defibrillators) represents the gold standard for asymptomatic
arrhythmia detection, due to their ability to provide complete
(uninterrupted) arrhythmia monitoring. Several studies have
evaluated the performance of intermittent ECG monitoring in
comparison to CIED monitoring (Figure 1). Ziegler et al. (2006)
performed a retrospective analysis of 574 CIED patients who
were known to have AF. In order to simulate the nature of inter-
mittent arrhythmia monitoring, the authors assessed the detec-
tion of atrial tachyarrhythmias (AT) or AF on randomly selected
days. When compared with continuous CIED monitoring, the
use of intermittent techniques had a significantly lower sensi-
tivity (31.3% for annual 24-h recordings, 54.2% for quarterly
24-h recordings, 71.0% for monthly 24-h recordings, 48.9% for
7-day monitoring, and 64.6% for 30-day monitoring) with a rel-
atively poor negative predictive value (21.5, 29.2, 39.4, 26.9, and
34.7%, respectively). Moreover, intermittent monitoring signifi-
cantly underestimated the overall AT/AF burden (P < 0.001).
Similar findings were reported by Botto et al. (2009) in a com-
parable patient population whereby the sensitivity for detecting
an AF episode lasting >5min was 44.4, 50.4, and 65.1% for 24-h,
1-week, and 1-month monitoring, respectively.
Leveraging the increased sensitivity and specificity associated
with these devices, there has been renewed interest in their abil-
ity to detect silent paroxysmal AF. In patients with a pacemaker
or defibrillator but without a known history of AF (or of oral
anticoagulation or antiarrhythmic drug use), the prevalence of
previously unrecognized paroxysmal AF was 30–35% (Healey
et al., 2012; Ziegler et al., 2012). In those with a history of stroke
or TIA and a clinical indication for pacemaker or defibrillator
implantation, interrogation of the device identified occult AF
(>5-min duration) in 28% over a mean follow-up of 1.1 ± 0.7
years (Ziegler et al., 2010). In this sub-analysis of the TRENDS
trial, most patients with AT/AF had infrequent episodes (73% had
AT/AF on<10% of recording days), and were first detected more
than 1 month after implant in 60%.
AF Detected by Insertable Cardiac
Monitors
While continuous arrhythmia monitoring provided by CIED is
clearly beneficial, their use is limited to patients with a clinical
indication for pacemaker or defibrillator implantation. In recent
years, the focus of long-term monitoring for cryptogenic stroke
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TABLE 3 | Clinical risk score.
STAF Score Points
Suissa et al. (2009)
Age >62 years 2
NIHSS Score ≥8 1
Left atrial dilatation 2
Absence of vascular etiology* 3
Interpretation
Score ≥5 = sensitivity 89%, specificity 88%
Fujii et al. (2013)
Mitral valve disease 1
NIHSS Score ≥8 1
Left atrial dilatation (>3.8 cm) 1
BNP ≥ 144pg/ml 2
Interpretation
Score ≥3 = sensitivity 78%, specificity 83%
*Defined by the absence of symptomatic extra- or intracranial stenosis ≥50%, symp-
tomatic arterial dissection, clinico-radiological lacunar syndrome. BNP, B-type Natriuretic
peptide; NIHSS, National Institutes of Health Stroke Scale; STAF, Score for the Targeting
of Atrial Fibrillation.
has shifted toward an evaluation of dedicated subcutaneous
monitors. The implantable cardiac monitor (ICM) or insertable
loop recorder (ILR) is a subcutaneous device implanted in the
left pectoral region that is capable of continuous uninterrupted
arrhythmia monitoring. However, unlike atrial-based CIEDs,
these subcutaneous monitors do not sense endocardial atrial
activity well. Atrial arrhythmias are detected and classified by a
dedicated AF detection algorithm. This algorithm analyzes the
irregularity of successive R–R intervals over a minimum time
interval (usually 2min), classifying arrhythmias on the basis of
differences between consecutive R–R segments (e.g., Lorenz scat-
terplots that show the R–R interval as a function of the preceding
R–R intervals). The sensitivity and specificity of these monitors
are limited by extraneous noise (particularly myopotentials), fre-
quent atrial or ventricular premature beats, or pronounced sinus
arrhythmia, thus necessitating visual inspection of the recorded
2-min ECG strip for confirmation. As such, while these devices
are highly sensitive in detecting atrial arrhythmias (>95%), they
appear to lack specificity (Hindricks et al., 2010).
Despite these potential limitations, there has been recent
interest in the use of ICM-based AF detection in the evalu-
ation of cryptogenic stroke. To date, six observational studies
have assessed their dedicated AF detection algorithms as an
adjunct to standard investigations including cerebral imaging,
echocardiography, 12-lead ECG, inpatient telemetry, and 24-h
ambulatory ECG monitoring. While Dion et al. (2010) failed
to identify a single case of subclinical AF in 24 patients after
a mean 14.5 months of ICM monitoring, a significant bur-
den of subclinical AF was detected in five other observational
series (despite variable screening prior to device implantation
and variable duration of monitoring). The reason for this dis-
crepancy likely lies in the former’s use of an older ICM that
FIGURE 1 | Sensitivity and negative predictive value for identification
of patients with any atrial tachycardia/atrial fibrillation (AT/AF)
episodes identified by various intermittent monitoring methods,
utilizing continuous monitoring as the gold standard. Reproduced with
permission from Ziegler et al. (2006) (A) and Arya et al. (2007) (B).
relied on ventricular rate for detecting AF, a method that has
poor sensitivity and underestimates AF burden. When devices
with validated algorithms (i.e., Lorenz plots) for AF detection
were utilized, a high prevalence of occult AF was detected. Chris-
tensen et al. identified subclinical AF (≥2min) in 14 of 85
(16.1%) patients implanted with an ICM during an 18-month
study period (Christensen et al., 2014). The mean time to AF
detection was 109 days, and the majority of episodes were short
(2–10min duration). Cotter et al. (2013) identified subclinical
AF (≥2min) in 13 of 51 (25.5%) patients, with a median time
to AF detection of 48 days. Etgen et al. (2013) used a more
stringent definition (≥6min) and identified subclinical AF in
6 of 22 (27.3%) individuals, with a median time to detection
of 161 days. Rojo-Martinez et al. (2013) detected subclinical
AF (≥2min) in 34 of 101 (33.7%) individuals over a median
follow-up of 281 days. Lastly, Ritter et al. (2013) evaluated 60
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patients presenting with acute cryptogenic stroke. After a
standard work-up, patients underwent ICM implantation an
average of 13 days after presentation followed by 7-day Holter
monitoring. After a minimum 12 months of follow-up, inter-
mittent AF lasting >2min was detected in 10 patients via
ICM (17%; average time to detection of 64 days), in con-
trast to only 1 (1.7%) with AF detected by 7-day Holter
monitoring.
Although there is a natural inclination to compare diagnos-
tic yields between studies, it is important to consider that several
factors obscure direct comparisons. Specifically, the prevalence
of AF may be influenced by inherent differences in patient
populations and the rigor of investigation in defining the eti-
ology of stroke as cryptogenic (e.g., inclusion of prolonged
in-hospital arrhythmia monitoring, transesophageal echocardio-
graphy (TEE), and screening for hypercoagulable states). Like-
wise, differences in study design could impact the amount of AF
detected through the use of variable monitoring durations (i.e.,
sensitivity increases with monitoring time) and non-uniform
definitions (e.g., higher prevalence expected with less stringent
definitions of continuous AF).
In order to address some of these limitations, the Cryptogenic
Stroke and underlying Atrial Fibrillation (CRYSTAL-AF) study
was designed as a large, prospective, multicenter, international,
randomized controlled trial (Sanna et al., 2014). A total of 441
patients with recent cryptogenic stroke or TIA (within 90 days;
mean 38.1 ± 27.6 days) but without a history of AF were ran-
domized 1:1 to standard arrhythmia monitoring (control arm;
n = 220) vs. implantation of a subcutaneous cardiac monitor
(ICM; n = 221). Prior to enrolment, alternate sources of stroke
were excluded by 12-lead ECG, 24-h ECGmonitoring, TEE, com-
puted tomographic angiography or magnetic resonance angiog-
raphy of the head and neck to rule out an arterial source, and
screening for hypercoagulable states in patients younger than 55
years. The primary endpoint was time to detection of AF (last-
ing more than 30 s) within 6 months after stroke. The rate of AF
detection at 6 months was 8.9% (n = 19) in the ICM group com-
pared to 1.4% (n = 3) in the control group [hazard ratio (HR),
6.4; 95%CI 1.9–21.7; P < 0.001]. When monitoring continued
from 6 through 12 months, an additional 10 first episodes of AF
were detected (12.4%; n = 29) in the ICM group vs. 1 in the
control group (2.0%; n = 4). The median time from random-
ization to detection of AF was 84 days in the ICM group and
53 days in the control group. At 12 months, 121 ECGs, 32 24-h
Holter monitors, and 1 event recorder were required to iden-
tify AF in 4 patients in the standard monitoring group. The first
episode of AF was asymptomatic in 23 of 29 patients randomized
to ICM monitoring (79%) and in 2 of 4 patients in the con-
trol group (50%), reinforcing the limitations of symptom-driven
or intermittent short-term monitoring. At 12 months, ischemic
stroke or TIA occurred in 15 subjects (7.1%) in the ICM group
vs. 19 (9.1%) in the control group. The most common adverse
events associated with ICM were infection [3 subjects (1.4%)],
pain [3 subjects (1.4%)], and irritation or inflammation [4 sub-
jects (1.9%)] at the insertion site. The ICM remained inserted
in 98.1% of subjects at 6 months and in 96.6% of subjects at 12
months.
AF Episode duration and the Risk of
Thromboembolism
The detection of AF on prolonged cardiac monitoring is lim-
ited by the specificity of its clinical significance. As outlined
above, increasing the duration and frequency of monitoring will
increase the detection rate of occult or subclinical AF. How-
ever, even in the context of prior thromboembolism, the rele-
vance of short, asymptomatic occult AF episodes remains poorly
understood. To this end, several series examining occult AF on
implantable devices have attempted to identify a threshold AF
duration associated with adverse clinical consequences such as
thromboembolism. Despite widespread interest, reported thresh-
old durations are highly variable, ranging from 5min by Glotzer
et al. (2003, 2009) (2.8 greater risk for stroke or death), to 6min
by Healey et al. (2012) (2.5 greater risk for thromboembolism),
to 24 h by Capucci et al. (2005) (3.1 greater risk for thromboem-
bolism). Likewise, a daily burden of 3.8 h (Shanmugam et al.,
2012) and 5.5 h (Glotzer et al., 2009) has also been associated with
significant increases in the risk of stroke (9 and 2-fold increases,
respectively).
Several authors have attempted to integrate clinical parame-
ters with AF episode duration/burden in order to refine stroke
risk stratification (Botto et al., 2009; Boriani et al., 2011).
Botto et al. (2009) demonstrated that by combining AF pres-
ence/duration with the CHADS2 score, risk prediction could be
improved: a low risk of stroke (0.8%) was observed in patients
with <5min of AF and a CHADS2 score ≤2, AF lasting 5min
to 24 h with and a CHADS2 score ≤1, and AF lasting >24 h
with a CHADS2 score of 0. In a separate series, improved speci-
ficity was observed through an integration of the CHA2DS2VASC
score and AF episode duration/burden (Boriani et al., 2011). Of
note, in this population of patients with a history of paroxys-
mal atria tachycardias who were implanted with a dual chamber
pacemaker the use of the CHA2DS2VASC score alone conferred
100% sensitivity to predict thromboembolism, albeit with poor
specificity (7% for a score ≥1 and 24% for a score ≥2). However,
the integration of AF presence/duration/burden improved the c-
statistic from 0.653 to 0.713 for CHADS2 and 0.898 to 0.910 for
CHA2DS2VASC (Boriani et al., 2011).
Temporal Proximity of Device-Detected AF
to Stroke Events
Although an association with thromboembolism has been estab-
lished, short episodes of AF on long-term arrhythmia mon-
itoring does not confer causality as the putative mechanism
(Figure 2). For example, the Asymptomatic Atrial Fibrillation
and Stroke Evaluation in Pacemaker Patients and the Atrial Fib-
rillation Reduction Atrial Pacing Trial (ASSERT) enrolled 2580
patients aged ≥65 years with hypertension but no history of
atrial fibrillation. A significant association between subclinical
AF (SCAF) >6min in duration and ischemic stroke or systemic
embolism was reported (hazard ratio, 2.49; 95% CI, 1.28–4.85;
P = 0.007) (Healey et al., 2012). Interestingly, the temporal
relationship between SCAF and stroke or thromboembolism was
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FIGURE 2 | The relationship of device-detected AF episodes to clinical
thromboembolic events (TE) in three studies (ASSERT, TRENDS, and
IMPACT). The left graph displays the prevalence of AF on CIED at any point
prior to index thromboembolism (TE), the middle graph in the 30 days prior to
TE, and the right graph after the index TE.
variable, with 2% of patients having SCAF at the time of stroke or
systemic embolism, a further 6% having SCAF detected within
30 days before stroke or systemic embolism, 28% with SCAF
detected >30 days before stroke or systemic embolism, and 16%
with SCAF detected only after their stroke, despite continuous
monitoring for a median duration of 228 days before their event
(Brambatti et al., 2014). As such, it is possible that short episodes
of AF identify patients with either more prolonged episodes of
paroxysmal AF (i.e., of sufficient duration to result in throm-
boembolism), or alternately, act as a marker for co-morbidities
that promote non-cardioembolic stroke and AF (e.g., relatively
more severe hypertension).
Conclusions and Perspectives
Oral anticoagulation is substantially more effective than
antiplatelet therapy for the prevention of ischemic stroke
associated with AF, pr ompting much interest and progress
in diagnosing occult AF in the setting of cryptogenic stroke.
Technological advancements have paved the way for extended
arrhythmia monitoring devices to enhance the diagnostic yield
in the work-up for cryptogenic stroke by revealing brief and rare
episodes of AF that would have otherwise escaped detection.
Nevertheless, several uncertainties remain. Prospective studies
are required to (1) evaluate the optimal duration and method
of rhythm monitoring, (2) characterize the ideal population for
extended rhythm monitoring, (3) determine the optimal defini-
tion of SCAF that warrants intervention (e.g., standard definition
of 30 s of sustained AF vs. 6min as used in ASSERT), and (4)
evaluate whether intervention results in improved outcomes
(i.e., how does initiation of oral anti-thrombotic therapy for
SCAF influence the rate of stroke or systemic embolism during
long-term follow-up?)
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